Celgene Corp (CELG) 106.78 $CELG
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous
at The Street - 1 hr 35 mins ago
It's hard to be skeptical about high-flying stocks when the bulls are making money right now, Cramer says.
MMM: 160.15 (+1.46), AMZN: 324.93 (+1.88), JEC: 47.70 (+0.47), ACT: 269.60 (+21.66), HD: 95.98 (-2.05), BX: 32.61 (+0.59), DPLO: 24.01 (-0.09), UNH: 98.19 (+1.72), DECK: 92.20 (-0.52), COLM: 41.65 (+0.20), ALKS: 52.94 (+1.30), ADT: 35.37 (-0.03), CELG: 106.78 (+2.42), VE: 17.88 (+0.21), URBN: 28.79 (-2.04), AGN: 213.37 (+4.17), HLT: 25.61 (+0.19), AA: 17.16 (+0.33), RIG: 25.85 (-0.35), WMB: 54.54 (+0.23), PF: 32.48 (-1.24), PPG: 208.50 (+3.17), WPZ: 52.50 (+0.52)
Final Glance: Biotechnology companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
at The Street - Tue Nov 18, 5:02PM CST
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
AGIO: 83.81 (-1.07), CELG: 106.78 (+2.42)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), MRK: 59.89 (+0.43), AMGN: 162.24 (+3.10), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27), CELG: 106.78 (+2.42)
Midday Glance: Biotechnology companies
AP - Tue Nov 18, 12:24PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Early Glance: Biotechnology companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Celgene presents Phase 3 Otezla data
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 9:05AM CST
CELG: 106.78 (+2.42)
Oral OTEZLA(R) (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis
Business Wire - Tue Nov 18, 6:30AM CST
--Eighty four percent of patients who completed one year of treatment with OTEZLA continued on OTEZLA through week 104 in both trials
CELG: 106.78 (+2.42)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 305.56 (+3.14), GILD: 103.71 (+3.27), INCY: 69.64 (-0.06), ALXN: 192.37 (+5.59), CELG: 106.78 (+2.42)
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases
Business Wire - Mon Nov 17, 8:00AM CST
In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases.
CELG: 106.78 (+2.42), CELGZ: 3.12 (-0.09)
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), ABBV: 66.05 (+1.01), CELG: 106.78 (+2.42)
'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
at The Street - Sat Nov 15, 4:00AM CST
The trading panel took a look at gold prices, which climbed 2.3% on Friday, as well as the potential for a pullback in biotech stocks.
AMZN: 324.93 (+1.88), TSRO: 31.45 (+1.46), XBI: 171.38 (+3.00), IBB: 295.25 (+6.41), CELG: 106.78 (+2.42), GILD: 103.71 (+3.27), GLD: 115.05 (+1.00), MCD: 96.41 (+0.44), SLV: 15.55 (+0.05), GDX: 20.30 (+0.91), TWTR: 40.61 (+0.14), AAPL: 115.47 (+1.48), BABA: 110.81 (-3.44)
Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.42 (+0.53), ALXN: 192.37 (+5.59), FFIV: 127.84 (-0.02), ILMN: 189.85 (+6.94), SPR: 41.78 (+0.71), AAPL: 115.47 (+1.48), ATHM: 41.13 (-1.72), BITA: 93.99 (+4.61), CELG: 106.78 (+2.42)
Look for Shares of Celgene to Potentially Rebound after Yesterday's 3.15% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 3:41PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 106.78 (+2.42)
Watch for Celgene to Potentially Rebound After Falling 3.15% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 3:41PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 106.78 (+2.42)
Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - Fri Nov 14, 3:21PM CST
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 101.90 (+0.78), ILMN: 189.85 (+6.94), BITA: 93.99 (+4.61), CELG: 106.78 (+2.42)
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:40PM CST
Synageva BioPharma Corp. (GEVA) announced the presentation of new data from a phase III study on sebelipase alfa for LAL deficiency.
GEVA: 76.25 (-0.81), AKRX: 38.42 (+0.53), ADHD: 3.24 (-0.21), CELG: 106.78 (+2.42)
Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 305.56 (+3.14), NTES: 101.90 (+0.78), HAL: 48.54 (-0.69), BITA: 93.99 (+4.61), BHI: 63.55 (-1.68), CELG: 106.78 (+2.42)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 305.56 (+3.14), AMZN: 324.93 (+1.88), HAL: 48.54 (-0.69), ILMN: 189.85 (+6.94), BITA: 93.99 (+4.61), BHI: 63.55 (-1.68), CELG: 106.78 (+2.42)
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous
at The Street - 1 hr 35 mins ago
It's hard to be skeptical about high-flying stocks when the bulls are making money right now, Cramer says.
MMM: 160.15 (+1.46), AMZN: 324.93 (+1.88), JEC: 47.70 (+0.47), ACT: 269.60 (+21.66), HD: 95.98 (-2.05), BX: 32.61 (+0.59), DPLO: 24.01 (-0.09), UNH: 98.19 (+1.72), DECK: 92.20 (-0.52), COLM: 41.65 (+0.20), ALKS: 52.94 (+1.30), ADT: 35.37 (-0.03), CELG: 106.78 (+2.42), VE: 17.88 (+0.21), URBN: 28.79 (-2.04), AGN: 213.37 (+4.17), HLT: 25.61 (+0.19), AA: 17.16 (+0.33), RIG: 25.85 (-0.35), WMB: 54.54 (+0.23), PF: 32.48 (-1.24), PPG: 208.50 (+3.17), WPZ: 52.50 (+0.52)
Final Glance: Biotechnology companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
at The Street - Tue Nov 18, 5:02PM CST
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
AGIO: 83.81 (-1.07), CELG: 106.78 (+2.42)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), MRK: 59.89 (+0.43), AMGN: 162.24 (+3.10), ABBV: 66.05 (+1.01), BMY: 58.70 (+0.27), CELG: 106.78 (+2.42)
Midday Glance: Biotechnology companies
AP - Tue Nov 18, 12:24PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Early Glance: Biotechnology companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 103.71 (+3.27), AMGN: 162.24 (+3.10), CELG: 106.78 (+2.42)
Celgene presents Phase 3 Otezla data
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 9:05AM CST
CELG: 106.78 (+2.42)
Oral OTEZLA(R) (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis
Business Wire - Tue Nov 18, 6:30AM CST
--Eighty four percent of patients who completed one year of treatment with OTEZLA continued on OTEZLA through week 104 in both trials
CELG: 106.78 (+2.42)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 305.56 (+3.14), GILD: 103.71 (+3.27), INCY: 69.64 (-0.06), ALXN: 192.37 (+5.59), CELG: 106.78 (+2.42)
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases
Business Wire - Mon Nov 17, 8:00AM CST
In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases.
CELG: 106.78 (+2.42), CELGZ: 3.12 (-0.09)
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), ABBV: 66.05 (+1.01), CELG: 106.78 (+2.42)
'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
at The Street - Sat Nov 15, 4:00AM CST
The trading panel took a look at gold prices, which climbed 2.3% on Friday, as well as the potential for a pullback in biotech stocks.
AMZN: 324.93 (+1.88), TSRO: 31.45 (+1.46), XBI: 171.38 (+3.00), IBB: 295.25 (+6.41), CELG: 106.78 (+2.42), GILD: 103.71 (+3.27), GLD: 115.05 (+1.00), MCD: 96.41 (+0.44), SLV: 15.55 (+0.05), GDX: 20.30 (+0.91), TWTR: 40.61 (+0.14), AAPL: 115.47 (+1.48), BABA: 110.81 (-3.44)
Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.42 (+0.53), ALXN: 192.37 (+5.59), FFIV: 127.84 (-0.02), ILMN: 189.85 (+6.94), SPR: 41.78 (+0.71), AAPL: 115.47 (+1.48), ATHM: 41.13 (-1.72), BITA: 93.99 (+4.61), CELG: 106.78 (+2.42)
Look for Shares of Celgene to Potentially Rebound after Yesterday's 3.15% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 3:41PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 106.78 (+2.42)
Watch for Celgene to Potentially Rebound After Falling 3.15% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 3:41PM CST
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 106.78 (+2.42)
Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - Fri Nov 14, 3:21PM CST
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 101.90 (+0.78), ILMN: 189.85 (+6.94), BITA: 93.99 (+4.61), CELG: 106.78 (+2.42)
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:40PM CST
Synageva BioPharma Corp. (GEVA) announced the presentation of new data from a phase III study on sebelipase alfa for LAL deficiency.
GEVA: 76.25 (-0.81), AKRX: 38.42 (+0.53), ADHD: 3.24 (-0.21), CELG: 106.78 (+2.42)
Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 305.56 (+3.14), NTES: 101.90 (+0.78), HAL: 48.54 (-0.69), BITA: 93.99 (+4.61), BHI: 63.55 (-1.68), CELG: 106.78 (+2.42)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 305.56 (+3.14), AMZN: 324.93 (+1.88), HAL: 48.54 (-0.69), ILMN: 189.85 (+6.94), BITA: 93.99 (+4.61), BHI: 63.55 (-1.68), CELG: 106.78 (+2.42)
